Discovery of Novel Amphipathic Ligands for the Dynorphin Binding Site on the Bradykinin Receptor

Case ID:

This invention is a dynorphin analog designed to interact with a receptor that is partly responsible for pain sensations. Dynorphin analog targets the bradykinin receptors instead of the f NMDA receptors. The ligands are novel in the deletion of an arginine residue in position 7 which has been recognized as an essential residue for opioid and non-opioid activities. This deletion has been shown to retain biological activity for the receptor. The researchers have also identified the minimum pharmacophore (combination of more than 2 basic amino acids and 2 hydrophobic amino acids) for the bradykinin receptor.


  • Use as an analgesic, specifically analgesia against chronic pain
  • Another potential application for this invention is use as an anti-inflammatory drug
  • There is a possibility, that with little to no modification. This particular dynorphin analog can be used to treat mild inflammation
  • Has potential application in pain modulation and analgesia


  • The dynorphin analog targets a different pathway, bradykinin receptors instead of NMDA receptors, to offer pain relief without the standard side effects
  • The series of dimorphic A analogs show therapeutic benefit to modulate pain, since it has been shown that up-regulation of dynorphin causes hyperalgesia by interacting with the bradykinin receptor


Status: issued U.S. patent #10,428,115

Patent Information:
Contact For More Information:
Mitch Graffeo
Sr. Licensing Manager - COM-T
The University of Arizona
Lead Inventor(s):
Yeon Sun Lee
Victor Hruby
Josephine Lai
Frank Porreca
[des-Arg7]-dynorphin analogs
amphipathic bradykinin receptor
non-opioid effect of dynorphin